Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.
Latest Information Update: 13 Jan 2025
Price :
$35 *
At a glance
- Drugs Lenalidomide (Primary) ; CAR-T cell therapies; Cyclophosphamide; Fludarabine; Ibrutinib
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 13 Jan 2025 New trial record